Broad Institute Comprehensive Screening Center

21世纪的生物医学研究人员工作在人类疾病理解爆炸的中心。人类和各种传染性生物等相关基因组的完整序列，为下一步探索疾病的分子机制奠定了基础。布罗德研究所的研究人员在这场革命的早期阶段就认识到，对小分子表型变化背后的细胞通路的扰动，将使解剖细胞回路和疾病生物学成为可能，从而为纠正人类疾病开辟了一条道路。在过去的十年中，我们在一个开放的数据共享环境中以生产模式运营筛选设施，创建了第一个综合和公共的小分子数据库和分析环境，包含超过2000万的结合和分析井测量，一个新的化学生物学信息模型和许多强大的分析工具，并于2007年在人员，筛选自动化，LIMS和机器人技术大大提高了这些已经很重要的生产能力。该筛选设施位于一个丰富的环境中，专注于小分子和小分子筛选，与疾病生物学和基因组生物学相结合。我们在此提出一项计划，在哈佛大学和麻省理工学院的布罗德研究所（BCSC）运营一个综合筛查中心，通过与更广泛的MLPCN研究社区合作，利用和补充现有的组织和基础设施倡议。

Biomedical researchers in the 21st century work in the epicenter of an explosion in the understanding of human disease. The complete sequences of relevant genomes, like the human and various infectious organisms, lay the foundation for the next steps in probing molecular mechanisms of disease. Broad Institute researchers recognized at an early stage of this revolution that the perturbation of the cellular pathways that underlie phenotypic changes with small molecules will make it possible to dissect cell circuitry and disease biology, thus enabling a path forward to correcting human diseases. We have operated a Screening Facility in a production mode over the past ten years in an open data-sharing environment, created the first comprehensive and public small-molecule database and analysis environment containing over 20 million binding and assay-well measurements, a novel chemical biology information model and many powerful analysis tools, and, in 2007, made a substantial investment in personnel, screening automation, LIMS and robotics that has substantially increased these already significant production capabilities. This screening facility resides within a rich environment focused on small molecules and small-molecule screening integrated with disease biology and genome biology. We propose here a plan to operate a Comprehensive Screening Center at the Broad Institute of Harvard and MIT (BCSC), leveraging and complementing existing organizational and infrastructure initiatives by collaborating with a wider MLPCN research community.